

## Special Issue

# COVID Vaccines: Design, Development, and Immune Response Studies

### Message from the Guest Editors

COVID-19 vaccines have represented an unprecedented effort to contain a pandemic. Developed at record time, they have saved millions of lives over the past couple of years. Nevertheless, there is still room for improvement at different fronts, ranging from the elicitation of mucosal immunity and the prevention of transmission to the ability to elicit greater immune responses in immunocompromised patients. While it is currently not clear whether yearly boosts will continue to be required, multivalent vaccines based on updated versions of the Spike protein are under development, as well as vaccines based on SARS-CoV-2 antigens other than Spike, and combo vaccines with flu and pneumococcus. In this Special Issues, we welcome original research and systematic reviews on vaccine design, immune responses, and different boosting protocols.

### Guest Editors

Dr. Fabrizio Maggi

Department of Medicine and Surgery, University of Insubria, 21100 Varese, Italy

Dr. Licia Bordi

Laboratory of Virology, National Institute for Infectious Diseases "L. Spallanzani", Via Portuense 292, 00149 Rome, Italy

### Deadline for manuscript submissions

closed (31 May 2024)



## Vaccines

an Open Access Journal  
by MDPI

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/148531](https://mdpi.com/si/148531)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,  
University of Georgia, Athens, GA 30602-7387, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).